In conclusion, the present study reveals a previously unrecognized role of diosmin, a conventional drug features long-time clinical use and safeness, in improving insulin sensitivity by blocking PPARγ phosphorylation and reducing obesity without the side effects of classic PPARγ full agonists. The gene discussed is PPARG; the disease is obesity due to melanocortin 4 receptor deficiency.